Literature DB >> 21079547

Urinary cell levels of mRNA for OX40, OX40L, PD-1, PD-L1, or PD-L2 and acute rejection of human renal allografts.

Cheguevara Afaneh1, Thangamani Muthukumar, Michelle Lubetzky, Ruchuang Ding, Catherine Snopkowski, Vijay K Sharma, Surya Seshan, Darshana Dadhania, Joseph E Schwartz, Manikkam Suthanthiran.   

Abstract

BACKGROUND: The positive costimulatory proteins OX40 and OX40L and negative regulatory proteins programmed death (PD)-1, PD ligand 1, and PD ligand 2 have emerged as significant regulators of acute rejection in experimental transplantation models.
METHODS: We obtained 21 urine specimens from 21 renal allograft recipients with graft dysfunction and biopsy-confirmed acute rejection and 25 specimens from 25 recipients with stable graft function and normal biopsy results (stable). Urinary cell levels of mRNAs were measured using real-time quantitative polymerase chain reaction assays, and the levels were correlated with allograft status and outcomes.
RESULTS: Levels of OX40 mRNA (P<0.0001, Mann-Whitney test), OX40L mRNA (P=0.0004), and PD-1 mRNA (P=0.004), but not the mRNA levels of PD ligand 1 (P=0.08) or PD ligand 2 (P=0.20), were significantly higher in the urinary cells from the acute rejection group than the stable group. Receiver operating characteristic curve analysis demonstrated that acute rejection is predicted with a sensitivity of 95% and a specificity of 92% (area under the curve=0.98, 95% confidence interval 0.96-1.0, P<0.0001) using a combination of levels of mRNA for OX40, OX40L, PD-1, and levels of mRNA for the previously identified biomarker Foxp3. Within the acute rejection group, levels of mRNA for OX40 (P=0.0002), OX40L (P=0.0004), and Foxp3 (P=0.04) predicted acute rejection reversal, whereas only OX40 mRNA levels (P=0.04) predicted graft loss after acute rejection.
CONCLUSION: A linear combination of urinary cell levels of mRNA for OX40, OX40L, PD-1, and Foxp3 was a strong predictor of acute rejection in human renal allograft biopsies. This prediction model should be validated using an independent cohort of renal allograft recipients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21079547      PMCID: PMC3033230          DOI: 10.1097/TP.0b013e3181ffbadd

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  28 in total

1.  Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine.

Authors:  B Li; C Hartono; R Ding; V K Sharma; R Ramaswamy; B Qian; D Serur; J Mouradian; J E Schwartz; M Suthanthiran
Journal:  N Engl J Med       Date:  2001-03-29       Impact factor: 91.245

2.  Critical role of OX40 in CD28 and CD154-independent rejection.

Authors:  Gülçin Demirci; Farhana Amanullah; Reshma Kewalaramani; Hideo Yagita; Terry B Strom; Mohamed H Sayegh; Xian Chang Li
Journal:  J Immunol       Date:  2004-02-01       Impact factor: 5.422

Review 3.  Pathways of allorecognition: implications for transplantation tolerance.

Authors:  David S Game; Robert I Lechler
Journal:  Transpl Immunol       Date:  2002-08       Impact factor: 1.708

4.  B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function.

Authors:  H Tamura; H Dong; G Zhu; G L Sica; D B Flies; K Tamada; L Chen
Journal:  Blood       Date:  2001-03-15       Impact factor: 22.113

5.  Impact of acute rejection therapy on infections and malignancies in renal transplant recipients.

Authors:  B Jamil; K Nicholls; G J Becker; R G Walker
Journal:  Transplantation       Date:  1999-11-27       Impact factor: 4.939

6.  The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion.

Authors:  I Gramaglia; A Jember; S D Pippig; A D Weinberg; N Killeen; M Croft
Journal:  J Immunol       Date:  2000-09-15       Impact factor: 5.422

7.  OX40 is required for regulatory T cell-mediated control of colitis.

Authors:  Thibault Griseri; Mark Asquith; Claire Thompson; Fiona Powrie
Journal:  J Exp Med       Date:  2010-04-05       Impact factor: 14.307

8.  Stimulating PD-1-negative signals concurrent with blocking CD154 co-stimulation induces long-term islet allograft survival.

Authors:  Wenda Gao; Gülçin Demirci; Terry B Strom; Xian Chang Li
Journal:  Transplantation       Date:  2003-09-27       Impact factor: 4.939

9.  Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients.

Authors:  Rami T Bustami; Akinlolu O Ojo; Robert A Wolfe; Robert M Merion; William M Bennett; Suzanne V McDiarmid; Alan B Leichtman; Philip J Held; Friedrich K Port
Journal:  Am J Transplant       Date:  2004-01       Impact factor: 8.086

Review 10.  T-cell costimulatory pathways in allograft rejection and tolerance.

Authors:  David M Rothstein; Mohamed H Sayegh
Journal:  Immunol Rev       Date:  2003-12       Impact factor: 12.988

View more
  25 in total

1.  Protein microarrays discover angiotensinogen and PRKRIP1 as novel targets for autoantibodies in chronic renal disease.

Authors:  Atul J Butte; Tara K Sigdel; Persis P Wadia; David B Miklos; Minnie M Sarwal
Journal:  Mol Cell Proteomics       Date:  2010-12-23       Impact factor: 5.911

Review 2.  Moving Biomarkers toward Clinical Implementation in Kidney Transplantation.

Authors:  Madhav C Menon; Barbara Murphy; Peter S Heeger
Journal:  J Am Soc Nephrol       Date:  2017-01-06       Impact factor: 10.121

Review 3.  Advances in Detection of Kidney Transplant Injury.

Authors:  Sanjeeva Herath; Jonathan Erlich; Amy Y M Au; Zoltán H Endre
Journal:  Mol Diagn Ther       Date:  2019-06       Impact factor: 4.074

Review 4.  Biomarkers for kidney transplant rejection.

Authors:  Denise J Lo; Bruce Kaplan; Allan D Kirk
Journal:  Nat Rev Nephrol       Date:  2014-01-21       Impact factor: 28.314

5.  Urinary cell transcriptomics and acute rejection in human kidney allografts.

Authors:  Akanksha Verma; Thangamani Muthukumar; Hua Yang; Michelle Lubetzky; Michael F Cassidy; John R Lee; Darshana M Dadhania; Catherine Snopkowski; Divya Shankaranarayanan; Steven P Salvatore; Vijay K Sharma; Jenny Z Xiang; Iwijn De Vlaminck; Surya V Seshan; Franco B Mueller; Karsten Suhre; Olivier Elemento; Manikkam Suthanthiran
Journal:  JCI Insight       Date:  2020-02-27

Review 6.  Immunologic monitoring in transplantation revisited.

Authors:  Paolo Cravedi; Peter S Heeger
Journal:  Curr Opin Organ Transplant       Date:  2012-02       Impact factor: 2.640

Review 7.  Allograft rejection and tubulointerstitial fibrosis in human kidney allografts: interrogation by urinary cell mRNA profiling.

Authors:  Thangamani Muthukumar; John R Lee; Darshana M Dadhania; Ruchuang Ding; Vijay K Sharma; Joseph E Schwartz; Manikkam Suthanthiran
Journal:  Transplant Rev (Orlando)       Date:  2014-05-27       Impact factor: 3.943

8.  MicroRNA profiles in allograft tissues and paired urines associate with chronic allograft dysfunction with IF/TA.

Authors:  M J Scian; D G Maluf; K G David; K J Archer; J L Suh; A R Wolen; M U Mba; H D Massey; A L King; T Gehr; A Cotterell; M Posner; V Mas
Journal:  Am J Transplant       Date:  2011-07-27       Impact factor: 8.086

Review 9.  The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses.

Authors:  Lindsay K Ward-Kavanagh; Wai Wai Lin; John R Šedý; Carl F Ware
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

10.  HIV-infected kidney graft recipients managed with an early corticosteroid withdrawal protocol: clinical outcomes and messenger RNA profiles.

Authors:  Thangamani Muthukumar; Cheguevara Afaneh; Ruchuang Ding; Demetra Tsapepas; Michelle Lubetzky; Samantha Jacobs; John Lee; Vijay Sharma; Jun Lee; Darshana Dadhania; Choli Hartono; Jennifer McDermott; Meredith Aull; David Leeser; Sandip Kapur; David Serur; Manikkam Suthanthiran
Journal:  Transplantation       Date:  2013-03-15       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.